<DOC>
	<DOC>NCT00386763</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of artemether-lumefantrine against uncomplicated malaria caused P. falciparum in children of 5-35 kg bodyweight.</brief_summary>
	<brief_title>Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria, Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<criteria>male or female infants and children ≤12 years of age body weight of ≥5 kg and &lt;35 kg, with a confirmed diagnosis of uncomplicated malaria caused by the P. falciparum parasite complicated malaria persistent vomiting malaria due to parasites other than P. falciparum antimalarial treatment received in the past 2 weeks known chronic disease e.g. positive HIV status, severe cardiac, renal, or hepatic disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Marsh fever</keyword>
	<keyword>Plasmodium infections</keyword>
	<keyword>Remittent fever</keyword>
	<keyword>Paludism</keyword>
	<keyword>Artemether</keyword>
	<keyword>Artemisinins</keyword>
	<keyword>Malaria</keyword>
	<keyword>Benflumetol</keyword>
	<keyword>Lumefantrine</keyword>
</DOC>